SUPERNUS PHARMACEUTICALS, INC. Inventory, Finished Goods, Net of Reserves
SUPERNUS PHARMACEUTICALS, INC. (SUPN) had Inventory, Finished Goods, Net of Reserves of $33.80 million as of 2026-06-30, per its 10-Q filed 2026-08-03.
Financial Statements › Notes › Inventory, Net, Items Net of Reserve Alternative › Inventory, Finished Goods and Work in Process, Net of Reserves
us-gaap:InventoryFinishedGoodsNetOfReserves · last filed 2026-08-03
- 2026-06-30: Inventory, Finished Goods, Net of Reserves $33.80M.
- 2026-03-31: Inventory, Finished Goods, Net of Reserves $19.54M.
- 2025-12-31: Inventory, Finished Goods, Net of Reserves $21.12M.
- 2025-09-30: Inventory, Finished Goods, Net of Reserves $16.70M.
| Period end | Inventory, Finished Goods, Net of Reserves |
|---|---|
| 2026-06-30 | $33.80M 10-Q · filed 2026-08-03 |
| 2026-03-31 | $19.54M 10-Q · filed 2026-05-05 |
| 2025-12-31 | $21.12M 10-Q · filed 2026-08-03 |
| 2025-09-30 | $16.70M 10-Q · filed 2025-11-06 |
| 2025-06-30 | $19.95M 10-Q · filed 2025-08-05 |
| 2025-03-31 | $22.07M 10-Q · filed 2025-05-06 |
| 2024-12-31 | $16.44M 10-K · filed 2026-03-02 |
| 2024-09-30 | $24.31M 10-Q · filed 2024-11-04 |
| 2024-06-30 | $28.67M 10-Q · filed 2024-08-06 |
| 2024-03-31 | $33.03M 10-Q · filed 2024-05-08 |
| 2023-12-31 | $29.92M 10-K · filed 2025-02-25 |
| 2023-09-30 | $34.96M 10-Q · filed 2023-11-08 |
| 2023-06-30 | $38.81M 10-Q · filed 2023-08-08 |
| 2023-03-31 | $34.26M 10-Q · filed 2023-05-09 |
| 2022-12-31 | $35.01M 10-Q · filed 2023-11-08 |
| 2022-09-30 | $46.69M 10-Q · filed 2022-11-09 |
| 2022-06-30 | $40.54M 10-Q · filed 2022-08-08 |
| 2022-03-31 | $33.34M 10-Q · filed 2022-05-12 |
| 2021-12-31 | $32.92M 10-K · filed 2023-03-09 |
| 2021-09-30 | $12.54M 10-Q · filed 2021-11-05 |
| 2021-06-30 | $15.04M 10-Q · filed 2021-08-06 |
| 2021-03-31 | $14.91M 10-Q · filed 2021-05-07 |
| 2020-12-31 | $17.13M 10-K · filed 2022-04-13 |
| 2020-09-30 | $15.37M 10-Q · filed 2020-11-06 |
| 2020-06-30 | $17.42M 10-Q · filed 2020-08-17 |
| 2020-03-31 | $11.87M 10-Q · filed 2020-05-15 |
| 2019-12-31 | $10.62M 10-K · filed 2021-03-08 |
| 2019-09-30 | $13.18M 10-Q · filed 2019-11-08 |
| 2019-06-30 | $13.54M 10-Q · filed 2019-08-09 |
| 2019-03-31 | $15.48M 10-Q · filed 2019-05-10 |
| 2018-12-31 | $12.64M 10-K · filed 2020-02-28 |
| 2018-09-30 | $10.03M 10-Q · filed 2018-11-09 |
| 2018-06-30 | $11.62M 10-Q · filed 2018-08-09 |
| 2018-03-31 | $7.30M 10-Q · filed 2018-05-10 |
| 2017-12-31 | $4.44M 10-K · filed 2019-03-01 |
| 2017-09-30 | $8.08M 10-Q · filed 2017-11-09 |
| 2017-06-30 | $5.00M 10-Q · filed 2017-08-03 |
| 2017-03-31 | $5.46M 10-Q · filed 2017-05-09 |
| 2016-12-31 | $5.84M 10-K · filed 2018-03-01 |
| 2016-09-30 | $6.56M 10-Q · filed 2017-01-20 |
| 2016-06-30 | $7.20M 10-Q/A · filed 2017-01-23 |
| 2016-03-31 | $6.41M 10-Q/A · filed 2017-01-20 |
| 2015-12-31 | $5.75M 10-K · filed 2017-03-16 |
| 2015-09-30 | $7.09M 10-Q/A · filed 2017-01-20 |
| 2015-06-30 | $7.19M 10-Q/A · filed 2017-01-23 |
| 2015-03-31 | $4.24M 10-Q/A · filed 2017-01-20 |
| 2014-12-31 | $4.62M 10-Q/A · filed 2017-01-20 |
| 2014-09-30 | $3.45M 10-Q/A · filed 2017-01-20 |
| 2014-06-30 | $3.02M 10-Q · filed 2014-08-12 |
| 2014-03-31 | $2.68M 10-Q · filed 2014-05-13 |
| 2013-12-31 | $1.91M 10-K · filed 2015-03-12 |
| 2013-09-30 | $1.73M 10-Q · filed 2013-11-13 |
| 2013-06-30 | $925.00K 10-Q · filed 2013-08-14 |
| 2013-03-31 | $128.00K 10-Q · filed 2013-05-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |